Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Polymers (Basel) ; 14(10)2022 May 22.
Artigo em Inglês | MEDLINE | ID: mdl-35631993

RESUMO

The sustainability, performance, and cost of production in the plywood industry depend on wood adhesives and the hot-pressing process. In this study, a cold-setting plywood adhesive was developed based on polyvinyl alcohol (PVOH), high-purity lignin, and hexamine. The influence of lignin content (10%, 15%, and 20%) and cold-pressing time (3, 6, 12, and 24 h) on cohesion, adhesion, and formaldehyde emission of plywood were investigated through physical, chemical, thermal, and mechanical analyses. The increased lignin addition level lowered the solids content, which resulted in reduced average viscosity of the adhesive. As a result, the cohesion strength of the adhesive formulation with 10% lignin addition was greater than those of 15% and 20% lignin content. Markedly, the adhesive formulation containing a 15% lignin addition level exhibited superior thermo-mechanical properties than the blends with 10% and 20% lignin content. This study showed that 10% and 15% lignin content in the adhesive resulted in better cohesion strength than that with 20% lignin content. However, statistical analysis revealed that the addition of 20% lignin in the adhesive and using a cold-pressing time of 24 h could produce plywood that was comparable to the control polyurethane resins, i.e., dry tensile shear strength (TSS) value of 0.95 MPa, modulus of rupture (MOR) ranging from 35.8 MPa, modulus of elasticity (MOE) values varying from 3980 MPa, and close-to-zero formaldehyde emission (FE) of 0.1 mg/L, which meets the strictest emission standards. This study demonstrated the feasibility of fabricating eco-friendly plywood bonded with PVOH-lignin-hexamine-based adhesive using cold pressing as an alternative to conventional plywood.

2.
Ophthalmology ; 118(4): 636-41, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21055812

RESUMO

PURPOSE: To evaluate the effects of intervals between preoperative intravitreal injection of bevacizumab (IVB) and surgery on the components of removed diabetic fibrovascular proliferative membranes. DESIGN: Interventional, consecutive, prospective, comparative case series. PARTICIPANTS: A total of 52 eyes of 49 patients with active diabetic fibrovascular proliferation with complications necessitating vitrectomy. METHODS: Participant eyes that had IVB were divided into 8 groups in which vitreoretinal surgery was performed at days 1, 3, 5, 7, 10, 15, 20, and 30 postinjection. A group of eyes with the same diagnosis and surgical intervention without IVB injection was used for comparison. In all eyes, proliferative membrane specimens obtained during vitrectomy were sent for histopathologic examination using hematoxylin-eosin stain, immunohistochemistry (CD34 and smooth muscle actin), and Masson's trichrome stain. MAIN OUTCOME MEASURES: Comparative analysis of different components of the fibrovascular proliferation (CD34, smooth muscle actin, and collagen) among the study groups. RESULTS: Pan-endothelial marker CD34 expression levels starting from day 5 postinjection were significantly less than in the control group (P < 0.001), with minimum expression (1+) in all specimens removed at or after day 30 postinjection. Positive staining for smooth muscle actin was barely detected in the control eyes at day 1, and consistently intense at day 15 and beyond (P < 0.001). The expression level of trichrome staining was significantly high at day 10, compared with control eyes (P < 0.001), and continued to increase at subsequent surgical time points. CONCLUSIONS: A profibrotic switch was observed in diabetic fibrovascular proliferation after IVB, and our results suggest that at approximately 10 days post-IVB the vascular component of proliferation is markedly reduced, whereas the contractile components (smooth muscle actin and collagen) are not yet abundant.


Assuntos
Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Retinopatia Diabética/patologia , Membrana Epirretiniana/patologia , Neovascularização Retiniana/patologia , Vitrectomia , Actinas/metabolismo , Adulto , Idoso , Anticorpos Monoclonais Humanizados , Antígenos CD34/metabolismo , Bevacizumab , Colágeno/metabolismo , Terapia Combinada , Retinopatia Diabética/metabolismo , Retinopatia Diabética/terapia , Membrana Epirretiniana/metabolismo , Membrana Epirretiniana/terapia , Feminino , Humanos , Técnicas Imunoenzimáticas , Injeções Intravítreas , Masculino , Pessoa de Meia-Idade , Cuidados Pré-Operatórios , Estudos Prospectivos , Neovascularização Retiniana/metabolismo , Neovascularização Retiniana/terapia , Tomografia de Coerência Óptica , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...